1. Adopts the risk management evaluation for hexabromocyclododecane;

2. Decides, in accordance with paragraph 9 of Article 8 of the Convention, to recommend to the Conference of the Parties that it consider listing hexabromocyclododecane in Annexes A, B and/or C to the Convention;